CMPX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMPX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Compass Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 19.73.
Compass Therapeutics has a current ratio of 19.73. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Compass Therapeutics's Current Ratio or its related term are showing as below:
During the past 6 years, Compass Therapeutics's highest Current Ratio was 19.73. The lowest was 2.67. And the median was 9.51.
The historical data trend for Compass Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Current Ratio | Get a 7-Day Free Trial | 2.67 | 4.97 | 13.84 | 12.05 | 19.73 |
Compass Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Current Ratio | Get a 7-Day Free Trial | 12.05 | 16.41 | 18.07 | 18.26 | 19.73 |
For the Biotechnology subindustry, Compass Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Compass Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Current Ratio (A: Dec. 2023 ) | = | Total Current Assets (A: Dec. 2023 ) | / | Total Current Liabilities (A: Dec. 2023 ) |
= | 153.881 | / | 7.801 | |
= | 19.73 |
Compass Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as
Current Ratio (Q: Dec. 2023 ) | = | Total Current Assets (Q: Dec. 2023 ) | / | Total Current Liabilities (Q: Dec. 2023 ) |
= | 153.881 | / | 7.801 | |
= | 19.73 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (NAS:CMPX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Compass Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard S Lindahl | director | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Thomas J. Schuetz | director, officer: Chief Executive Officer | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
David M Wurzer | director | C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Vered Bisker-leib | officer: Chief Operating Officer | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
James P Boylan | director | C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025 |
Ellen Chiniara | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Philip Ferneau | director | 10 ALLEN STREET, HANOVER NH 03755 |
Orbimed Capital Gp V Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Miranda Jayne Toledano | director | C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135 |
Susan Kalled | officer: Chief Scientific Officer | COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135 |
Brett Kaplan | director | C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-08-2022
By Marketwired • 06-22-2023
By Value_Insider Value_Insider • 12-01-2022
By Value_Insider Value_Insider • 11-09-2022
By Value_Insider Value_Insider • 11-02-2022
By GuruFocusNews GuruFocusNews • 06-18-2022
By Marketwired • 11-07-2023
By sperokesalga sperokesalga • 03-28-2023
By PurpleRose PurpleRose • 08-02-2022
By Stock market mentor Stock market mentor • 02-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.